Do Pills Have No Ills?

Capturing the Impact of Direct Treatment Disutility

Alexander Thompson, Bruce Guthrie, Katherine Payne (Lead / Corresponding author)

    Research output: Contribution to journalEditorial

    3 Citations (Scopus)
    54 Downloads (Pure)

    Abstract

    Model-based economic evaluations should capture the impact on all costs and outcomes relevant to the chosen study perspective and time horizon. This editorial defines what is meant by direct treatment disutility (DTD) and describes why it could be an important harm that those designing model-based evaluations should consider. Some existing estimates of DTD identified from the current literature are summarised in terms of the methods used to elicit the values and the size of the estimated DTD. Model-based studies that include DTDs are also summarised. It was found that the values used within model-based economic evaluations (ranging from 0.00384 to 0.02) were typically smaller than the directly elicited values from the existing literature (0–0.033). Yet even with conservative estimates of DTDs, cost-effectiveness results were sensitive to their inclusion. The editorial concludes by discussing future methodological and empirical research needed to estimate more robust DTD values.

    Original languageEnglish
    Pages (from-to)333-336
    Number of pages4
    JournalPharmacoEconomics
    Volume34
    Issue number4
    Early online date8 Dec 2015
    DOIs
    Publication statusPublished - Apr 2016

    Fingerprint

    Cost-Benefit Analysis
    Empirical Research
    Costs and Cost Analysis

    Cite this

    Thompson, Alexander ; Guthrie, Bruce ; Payne, Katherine. / Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility. In: PharmacoEconomics. 2016 ; Vol. 34, No. 4. pp. 333-336.
    @article{00d8d3b76860491fb0d945df238055b3,
    title = "Do Pills Have No Ills?: Capturing the Impact of Direct Treatment Disutility",
    abstract = "Model-based economic evaluations should capture the impact on all costs and outcomes relevant to the chosen study perspective and time horizon. This editorial defines what is meant by direct treatment disutility (DTD) and describes why it could be an important harm that those designing model-based evaluations should consider. Some existing estimates of DTD identified from the current literature are summarised in terms of the methods used to elicit the values and the size of the estimated DTD. Model-based studies that include DTDs are also summarised. It was found that the values used within model-based economic evaluations (ranging from 0.00384 to 0.02) were typically smaller than the directly elicited values from the existing literature (0–0.033). Yet even with conservative estimates of DTDs, cost-effectiveness results were sensitive to their inclusion. The editorial concludes by discussing future methodological and empirical research needed to estimate more robust DTD values.",
    author = "Alexander Thompson and Bruce Guthrie and Katherine Payne",
    note = "The work underpinning the editorial was funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR) Programme (project number 11/2003/27).",
    year = "2016",
    month = "4",
    doi = "10.1007/s40273-015-0357-9",
    language = "English",
    volume = "34",
    pages = "333--336",
    journal = "PharmacoEconomics",
    issn = "1170-7690",
    publisher = "Springer Verlag",
    number = "4",

    }

    Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility. / Thompson, Alexander; Guthrie, Bruce; Payne, Katherine (Lead / Corresponding author).

    In: PharmacoEconomics, Vol. 34, No. 4, 04.2016, p. 333-336.

    Research output: Contribution to journalEditorial

    TY - JOUR

    T1 - Do Pills Have No Ills?

    T2 - Capturing the Impact of Direct Treatment Disutility

    AU - Thompson, Alexander

    AU - Guthrie, Bruce

    AU - Payne, Katherine

    N1 - The work underpinning the editorial was funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR) Programme (project number 11/2003/27).

    PY - 2016/4

    Y1 - 2016/4

    N2 - Model-based economic evaluations should capture the impact on all costs and outcomes relevant to the chosen study perspective and time horizon. This editorial defines what is meant by direct treatment disutility (DTD) and describes why it could be an important harm that those designing model-based evaluations should consider. Some existing estimates of DTD identified from the current literature are summarised in terms of the methods used to elicit the values and the size of the estimated DTD. Model-based studies that include DTDs are also summarised. It was found that the values used within model-based economic evaluations (ranging from 0.00384 to 0.02) were typically smaller than the directly elicited values from the existing literature (0–0.033). Yet even with conservative estimates of DTDs, cost-effectiveness results were sensitive to their inclusion. The editorial concludes by discussing future methodological and empirical research needed to estimate more robust DTD values.

    AB - Model-based economic evaluations should capture the impact on all costs and outcomes relevant to the chosen study perspective and time horizon. This editorial defines what is meant by direct treatment disutility (DTD) and describes why it could be an important harm that those designing model-based evaluations should consider. Some existing estimates of DTD identified from the current literature are summarised in terms of the methods used to elicit the values and the size of the estimated DTD. Model-based studies that include DTDs are also summarised. It was found that the values used within model-based economic evaluations (ranging from 0.00384 to 0.02) were typically smaller than the directly elicited values from the existing literature (0–0.033). Yet even with conservative estimates of DTDs, cost-effectiveness results were sensitive to their inclusion. The editorial concludes by discussing future methodological and empirical research needed to estimate more robust DTD values.

    UR - http://www.scopus.com/inward/record.url?scp=84961199515&partnerID=8YFLogxK

    U2 - 10.1007/s40273-015-0357-9

    DO - 10.1007/s40273-015-0357-9

    M3 - Editorial

    VL - 34

    SP - 333

    EP - 336

    JO - PharmacoEconomics

    JF - PharmacoEconomics

    SN - 1170-7690

    IS - 4

    ER -